Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light

Main Article Content

U Reinhold
Dermatological Center Bonn Friedensplatz, Bonn, Germany

T Dirschka
Centroderm GmbH, Wuppertal, Germany & Faculty of Health, University Witten-Herdecke, Witten, Germany

R Ostendorf
Private Practice, Moenchengladbach, Germany

R Aschoff
Department of Dermatology,University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

C Berking
University Hospital, Department of Dermatology and Allergology, Munich, Germany

W Philipp-Dormston
Medical Centre Cologne, Cologne, Germany

R.M. Szeimies
Vest Clinic, Department of Dermatology and Allergology, Recklinghausen, Germany

Keywords

actinic keratosis, photodynamic therapy, BF-200 ALA, narrowband red light

Abstract

Abstract not available.

References

1. Reinhold, Uwe (2017): A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. In: Future oncology (London, England) 13(27): S. 2413-2428. DOI: 10.2217/fon-2017-0247.

2. Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED® lamp. Br J Dermatol. 2016; 175(4):696-705.

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.49

Article Details

How to Cite
Reinhold, U., Dirschka, T., Ostendorf, R., Aschoff, R., Berking, C., Philipp-Dormston, W., & Szeimies, R. (2019). Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light. SKIN The Journal of Cutaneous Medicine, 3, S49. https://doi.org/10.25251/skin.3.supp.49
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)